Ladislau C Kovari
Overview
Explore the profile of Ladislau C Kovari including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Amblard F, LeCher J, De R, Zhou S, Liu P, Goh S, et al.
Eur J Med Chem
. 2024 Mar;
268:116263.
PMID: 38432056
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and related variants, are responsible for the devastating coronavirus disease 2019 (COVID-19) pandemic. The SARS-CoV-2 main protease (Mpro) plays a central role in...
2.
Mirza M, Alanko I, Vanmeert M, Muzzarelli K, Salo-Ahen O, Abdullah I, et al.
Eur J Pharm Sci
. 2022 May;
175:106220.
PMID: 35618201
With expanding recent outbreaks and a lack of treatment options, the Zika virus (ZIKV) poses a severe health concern. The availability of ZIKV NS2B-NS3 co-crystallized structures paved the way for...
3.
Chordia P, Dewdney T, Keusch B, Kuiper B, Ross K, Kovari I, et al.
Discoveries (Craiova)
. 2020 Apr;
2(4):e27.
PMID: 32309558
Treatment of Human Immunodeficiency Virus remains challenging due to the emergence of drug resistant strains under the selective pressure produced by standard anti-retroviral therapy. To explore the structural mechanisms of...
4.
Takamatsu Y, Aoki M, Bulut H, Das D, Amano M, Sheri V, et al.
Antimicrob Agents Chemother
. 2019 May;
63(8).
PMID: 31085520
Combination antiretroviral therapy has achieved dramatic reductions in the mortality and morbidity in people with HIV-1 infection. Darunavir (DRV) represents a most efficacious and well-tolerated protease inhibitor (PI) with a...
5.
Muzzarelli K, Kuiper B, Spellmon N, Brunzelle J, Hackett J, Amblard F, et al.
Biochemistry
. 2019 Jan;
58(7):900-907.
PMID: 30605321
Norovirus is the leading cause of acute gastroenteritis worldwide with a yearly reported 700 million cases driving a $60 billion global socioeconomic burden. With no United States Food and Drug...
6.
Amblard F, Zhou S, Liu P, Yoon J, Cox B, Muzzarelli K, et al.
Bioorg Med Chem Lett
. 2018 May;
28(12):2165-2170.
PMID: 29779977
A series of tripeptidyl transition state inhibitors with new P1 and warhead moieties were synthesized and evaluated in a GI-1 norovirus replicon system and against GII-4 and GI-1 norovirus proteases....
7.
Kuiper B, Muzzarelli K, Keusch B, Holcomb J, Amblard F, Liu P, et al.
Infect Disord Drug Targets
. 2018 May;
18(3):224-232.
PMID: 29779487
Background: Noroviruses are the leading cause of acute gastroenteritis worldwide. Norovirus proteases, which are responsible for cleavage of the viral polyprotein, have become an attractive drug target to treat norovirus...
8.
Kuiper B, Keusch B, Dewdney T, Chordia P, Ross K, Brunzelle J, et al.
Biochem Biophys Rep
. 2017 Nov;
2:160-165.
PMID: 29124158
HIV-1 protease (PR) is a 99 amino acid protein responsible for proteolytic processing of the viral polyprotein - an essential step in the HIV-1 life cycle. Drug resistance mutations in...
9.
Kuiper B, Slater K, Spellmon N, Holcomb J, Medapureddy P, Muzzarelli K, et al.
Biochem Biophys Res Commun
. 2017 Mar;
492(4):668-673.
PMID: 28342876
Zika virus (ZIKV) is a flavivirus spread by daytime-active Aedes spp. mosquitoes such as A. aegypti and A. albopictus. Previously thought to be a mild infection, the latest ZIKV outbreak...
10.
Yedidi R, Proteasa G, Martin P, Liu Z, Vickrey J, Kovari I, et al.
J Mol Graph Model
. 2014 Aug;
53:105-111.
PMID: 25108107
Human immunodeficiency virus type-1 (HIV-1) protease, a homodimeric aspartyl protease, is a critical drug target in designing anti-retroviral drugs to treat HIV/AIDS. Multidrug-resistant (MDR) clinical isolate-769 HIV-1 protease (PDB ID:...